Warnings mark a first for FDA about OTC topicals rendered unapproved due to labeling for STI treatment and latest action to ...
Kevin Lobo announced plans to step down as Stryker's CEO after 14 years in the role and 15 with the company, during which the ...
A bipartisan Senate bill that would end the Trump Administration’s 340B rebate model pilot and create a national claims ...
HHS' attorney said professional organizations cannot challenge the ACIP member appointments because no final agency action ...
Novo will not submit its Ozempic/Wegovy/Rybelsus franchise and AstraZeneca refused to enter its Calquence into the 340B ...
The National Institute of Allergy and Infectious Diseases also is weighing whether to participate in trials involving ...
Consumer health sales are growing across the Nordics and access to non-prescription products is widening, but Conaxess ...
CNS drug development has long presented significant challenges. Diseases can be severe and chronic, diagnoses may take years, ...
The global coalition of medicines regulatory authorities, ICMRA, is pressing regulators to align acceptance of non-animal ...
The long-acting injectable was superior to daily oral therapy at viral suppression in treatment-experienced patients who had ...
‘Worse Performance Than Previously Disclosed’ Prompts Class I Recall Of BD Alaris Infusion Pump Sets
The FDA has classified BD’s recall of certain Alaris Pump Infusion Sets as Class I after testing found the sets can perform worse than previously disclosed, potentially causing under- or over-infusion ...
ArriVent’s firmonertinib failed against chemo on PFS in NSCLC with exon 20 insertion mutations, but the firm also has the EGFR inhibitor in Phase III for the larger PACC mutation subpopulation.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results